Sign in
GRCL Stock Price, Chart, Stats & News
Gracell Biotechnologies Inc.
Save
197.97M
Market cap
–
Current P/E
–
Forward P/E
GRCL chart
1M
3M
1Y
5Y
Loading chart...
Fundamentals
Gross margin | – |
Operating margin | – |
Pretax margin | – |
Net margin | – |
Effective tax rate | -0.00% |
ROA | -36.68% |
ROE | -37.93% |
D/E | 0.13x |
Interest coverage ratio | -92.72x |
GRCL valuation
P/E | – |
P/S | – |
P/B | 0.70x |
P/CF | -0.29x |
P/FCF | -0.38x |
P/OCF | -0.29x |
PEG | -0.00x |
EV multiple | -4.64x |
About
Gracell Biotechnologies Inc. is a clinical-stage biopharmaceutical company focused on the discovery and advancement of cell-based therapies, primarily for cancer treatment, within the People's Republic of China. The company's leading investigational therapies include: GC012F: A FasTCAR-enhanced autologous CAR-T product designed to target both BCMA and CD19, currently undergoing Phase I clinical trials for multiple myeloma. GC019F: A FasTCAR-enabled CD19-directed autologous CAR-T therapy, which is progressing through Phase I trials for adult B-cell acute lymphoblastic leukemia (B-ALL) and is also in preclinical development for relapsed or refractory (r/r) B cell non-Hodgkin's lymphoma (B-NHL).
Similar securities
Based on sector and market capitalization
Report issue